NEW YORK (GenomeWeb) – Interleukin Genetics today announced it has received conditional approval from New York State to offer its genetic test for periodontal disease.

Also, the firm's VP of Development and Clinical Operations Lynn Doucette-Stamm has received a certification for qualification from the state as a lab director for genetic testing. She heads the Interleukin Clinical Operations and Research and Development teams.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.